Key Players
Competitive Landscape
Novel hypercholesterolemia drug competition includes established PCSK9 suppliers, oral nonstatin companies, RNA interference developers and gene-editing platforms. Marketed products compete on efficacy, route, cardiovascular evidence and payer access, while clinical-stage programs compete on durability and the quality of long-term safety data.
Recent activity has moved in three directions. Merck introduced oral PCSK9 inhibition, large pharmaceutical companies broadened their exposure to one-time genetic medicines and RNA interference programs advanced into later-stage familial hypercholesterolemia trials. Commercial selection now depends on how a modality fits the patient, the prescriber and the reimbursement pathway.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Merck received FDA approval for Lipfendra in July 2026 | Adults above LDL-C goals need an additional treatment that does not require injection | PCSK9 inhibition expands from antibodies and siRNA into a daily oral tablet | Retail and specialty pharmacy access for primary hypercholesterolemia and HeFH |
| Eli Lilly completed its acquisition of Verve Therapeutics in July 2025 | High-risk patients create demand for durable LDL-C reduction with fewer repeat doses | Large pharmaceutical companies are acquiring in vivo cardiovascular gene-editing capability | One-time PCSK9 or related genetic medicines if safety and durability are demonstrated |
| Arrowhead initiated the Phase 3 YOSEMITE study of zodasiran in July 2025 | Patients with HoFH need additional targets beyond LDL-receptor-dependent therapy | ANGPTL3 RNA interference advances into late-stage inherited lipid disease | Quarterly hepatic gene silencing for rare severe hypercholesterolemia |
Amgen, Novartis, Regeneron and Esperion continue to compete through marketed therapies, while CRISPR Therapeutics and Silence Therapeutics develop genetic or RNA-based approaches outside the three mapped actions.
Source: Future Market Insights, Novel Hypercholesterolemia Drugs Market report, 2026-2036.
Amgen and Novartis have broad commercial LDL-C platforms, Merck adds an oral PCSK9 route and Regeneron addresses homozygous familial hypercholesterolemia through ANGPTL3 inhibition. The remaining companies are differentiated by clinical stage, target and expected dosing model.
Which companies have marketed PCSK9 therapies?
Amgen markets Repatha, Novartis markets Leqvio and Merck markets Lipfendra in the USA. These products use a monoclonal antibody, siRNA and an oral macrocyclic peptide to inhibit the PCSK9 pathway through different dosing routes.
Which companies address homozygous familial hypercholesterolemia?
Regeneron markets Evkeeza for homozygous familial hypercholesterolemia, while Arrowhead is evaluating zodasiran in Phase 3. Amgen also includes homozygous familial hypercholesterolemia within the Repatha label for eligible patients.
Which companies are developing one-time gene-editing treatments?
Eli Lilly owns Verve Therapeutics and its cardiovascular base-editing platform, while CRISPR Therapeutics is evaluating CTX310 against ANGPTL3. Both approaches remain clinical-stage and require evidence on durability, safety and patient selection.
Which companies provide oral nonstatin options?
Merck provides oral PCSK9 inhibition through Lipfendra. Esperion provides bempedoic acid through Nexletol and the bempedoic acid plus ezetimibe combination Nexlizet, giving prescribers oral routes with different mechanisms.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Amgen Inc. | Global commercial platform | Repatha provides subcutaneous PCSK9 inhibition for hypercholesterolemia and cardiovascular risk reduction. |
| Novartis AG | Global long-acting platform | Leqvio uses inclisiran siRNA with maintenance dosing every six months after initial and three-month administration. |
| Regeneron Pharmaceuticals, Inc. | Rare lipid disease specialist | Evkeeza provides monthly intravenous ANGPTL3 inhibition for homozygous familial hypercholesterolemia. |
| Esperion Therapeutics, Inc. | Oral nonstatin platform | Nexletol and Nexlizet provide bempedoic acid-based LDL-C lowering with cardiovascular risk indications. |
| Merck & Co., Inc. | Oral PCSK9 entrant | Lipfendra provides once-daily oral PCSK9 inhibition for adults with hypercholesterolemia, including HeFH. |
| Arrowhead Pharmaceuticals, Inc. | Late-stage RNAi developer | Zodasiran targets hepatic ANGPTL3 production and is in Phase 3 for homozygous familial hypercholesterolemia. |
| Eli Lilly and Company | Strategic gene-editing owner | Lilly acquired Verve Therapeutics to advance one-time cardiovascular genetic medicines. |
| Verve Therapeutics, Inc. | Clinical-stage base editing | Verve develops in vivo PCSK9 base-editing programs within Eli Lilly. |
| CRISPR Therapeutics AG | Clinical-stage CRISPR platform | CTX310 targets ANGPTL3 through one-time in vivo CRISPR-Cas9 editing. |
| Silence Therapeutics plc | RNAi cardiovascular platform | Zerlasiran targets lipoprotein(a), an inherited lipid risk factor adjacent to LDL-C management. |
Research Methodology
The companies here show how competition is structured rather than ranking corporate size or revenue. Inclusion requires official evidence of a marketed hypercholesterolemia therapy, a relevant regulatory approval or a clinical program directed at LDL-C, familial hypercholesterolemia or an adjacent inherited lipid target. Product labels, regulator decisions, trial information, company filings and official announcements establish the role of each company. Geographic statements reflect documented product markets or clinical activity. Segment shares are FMI estimates for 2026 and remain separate from company positioning.
